{"entity":{"id":"nct06370754","kind":"trial","name":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","aka":["FD-IMPACT"],"tldr":"A phase 1/2 trial of liposomal irinotecan, fluorouracil (5-FU), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel), nab-paclitaxel and other drugs in pancreatic cancer, run by Fudan University, not yet recruiting.","summary":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment is a phase 1/2, interventional study registered as NCT06370754 by Fudan University, with a registry enrolment figure of 117 participants, started 2024-04-30 and due to reach its primary completion in 2026-04-30. Interventions recorded: JS001; JS004; JS007; JS015; Irinotecan Liposome Injection; 5-Fluorouracil (5-FU); Leucovorin (LV); Nab paclitaxel; Gemcitabine. Conditions listed: Pancreatic Cancer. Primary outcome: Incidence of dose-limiting toxicity (DLT) (phase IB); Objective Response Rate (ORR) (phase II). Pancreatic eligibility wording from the registry: \"* Patients with locally advanced unresectable or metastatic pancreatic cancer confirmed by histopathology or cytopathology (islet cell tumor is not eligible for inclusion) who meet the following requirements:\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06370754","url":"https://clinicaltrials.gov/study/NCT06370754"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["liposomal-irinotecan","fluorouracil","flot","nab-paclitaxel","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06370754","phase":"1/2","setting":"A Phase Ib/II Platform Trial of Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","sponsor":"Fudan University","enrolled":117,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06370754/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}